Zenith支架腹主动脉瘤腔内修复术十四年结局
单中心研究纳入2000至2011年接受Zenith支架择期EVAR的610例患者,平均随访99.2个月。14年总生存率24%,免于AAA破裂率98.1%,EVAR失败率21.6%。I/III型内漏、II型内漏和ASA 4级是EVAR失败的独立预测因素。
要点
- Zenith支架EVAR的14年免于AAA破裂率达98.1%,动脉瘤相关死亡风险低。
- 14年总生存率仅24%,远期总体生存仍不理想。
- I/III型内漏(HR 6.7)和II型内漏(HR 2.3)是EVAR失败的独立预测因素。
核心结论
- Zenith支架EVAR是安全且持久的修复方式,破裂和动脉瘤相关死亡风险低,但远期总生存率仍较差。
- 新支架模型评估时应考虑约四分之一患者在术后14年仍存活。
研究设计与样本
- 单中心回顾性研究,2000至2011年纳入610例择期接受Zenith支架EVAR的患者。
- 平均年龄73.2岁,平均动脉瘤直径55.3 mm,平均随访99.2个月(范围0-175个月)。
主要发现
- 围手术期死亡5例(0.8%),术中转开放3例。
- 随访期间发生7例AAA破裂,除1例外均致命。
- 总生存率1年92.8%±1.1%、5年70.1%±1.9%、10年37.8%±2.9%、14年24%±4%。
- 免于AAA破裂率1年99.8%±0.02、5年99.4%±0.04、10年和14年均为98.1%±0.07。
- 14年时EVAR失败发生于132例(21.6%)患者。
关键数值与推荐
- 免于晚期再干预和转开放率1年98%±0.6、5年87.7%±1.5、10年75.7%±3.2、14年69.9%±5.2。
- 免于瘤囊增大>5.0 mm率1年99.8%、5年96.6%±0.7、10年81.0%±3.4、14年74.1%±5.8%。
- 多因素分析显示I/III型内漏(HR 6.7;95%CI 4.6-9.7;P<.001)、II型内漏(HR 2.3;95%CI 1.6-3.4;P<.001)和ASA 4级(HR 1.6;95%CI 1.0-2.6;P=.034)是EVAR失败的独立预测因素。
临床怎么用
- Zenith支架EVAR术后需长期监测内漏,尤其I/III型和II型内漏,以降低EVAR失败风险。
- 评估新支架模型时应考虑患者14年远期生存可能,需验证其长期耐久性。
局限性
- 单中心回顾性研究,结果可能受中心经验和患者选择偏倚影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Long-term results of abdominal aortic aneurysm (AAA) endovascular repair are affected by graft design renewals that tend to improve the performance of older generation prostheses but usually reset the follow-up times to zero. The present study investigated the long-term outcomes of endovascular AAA repair (EVAR) using the Zenith graft, still in use without major modification, in a single center experience. METHODS: Between 2000 and 2011, 610 patients underwent elective EVAR using the Zenith endograft (Cook Inc, Bloomington, Ind) and represent the study group. Primary outcomes were overall survival, freedom from AAA rupture, and freedom from AAA-related death. Secondary outcomes included freedom from late (>30 days) reintervention, freedom from late (>30 days) conversion to open repair, freedom from aneurysm sac enlargement >5.0 mm and freedom from EVAR failure, defined as a composite of AAA-related death, AAA rupture, AAA growth >5 mm, and any reintervention. RESULTS: Mean age was 73.2 years. Mean aneurysm diameter was 55.3 mm. There were five perioperative deaths (0.8%) and three intraoperative conversions. At a mean follow-up of 99.2 (range, 0-175) months, seven AAA ruptures occurred, all fatal except one. Overall survival was 92.8% ± 1.1% at 1 year, 70.1% ± 1.9% at 5 years, 37.8% ± 2.9% at 10 years, and 24 ± 4% at 14 years. Freedom from AAA-rupture was 99.8% ± 0.02 at 1 year (one case), 99.4% ± 0.04 at 5 years (three cases), and 98.1% ± 0.07 at 10 and 14 years. Freedom from late reintervention and conversion was 98% ± 0.6 at 1 year, 87.7% ± 1.5 at 5 years, 75.7% ± 3.2 at 10 years, and 69.9% ± 5.2 at 14 years. Freedom from aneurysm sac growth >5.0 mm was 99.8% at 1 year, 96.6% ± 0.7 at 5 years, 81.0% ± 3.4 at 10 years, and 74.1% ± 5.8% at 14 years. EVAR failure occurred in 132 (21.6%) patients at 14 years. At multivariate analysis, independent predictors of EVAR failure resulted type I and III endoleak (hazard ratio [HR], 6.7; 95% confidence interval [CI], 4.6- 9.7; P < .001], type II endoleak (HR, 2.3; 95% CI, 1.6-3.4; P < .001), and American Society of Anesthesiologists grade 4 (HR, 1.6; 95% CI, 1.0-2.6; P = .034). CONCLUSIONS: EVAR with Zenith graft represents a safe and durable repair. Risk of rupture and aneurysm-related death is low, whereas overall long-term survival remains poor. Novel endograft models should be tested and evaluated considering that one-fourth of the operated patients will still be alive after 14 years.
引用
- Verzini F, Romano L, Parlani G, et al. Fourteen-year outcomes of abdominal aortic endovascular repair with the Zenith stent graft. J Vasc Surg. 2016. PMID: 27832988. doi:10.1016/j.jvs.2016.07.117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。